Testing for treatment-biomarker interaction based on local partial-likelihood

Stat Med. 2015 Nov 30;34(27):3516-30. doi: 10.1002/sim.6563. Epub 2015 Jun 17.

Abstract

In clinical trials, patients with different biomarker features may respond differently to the new treatments or drugs. In personalized medicine, it is important to study the interaction between treatment and biomarkers in order to clearly identify patients that benefit from the treatment. With the local partial-likelihood estimation (LPLE) method proposed by Fan J, Lin H, Zhou Y. Local partial-likelihood estimation for lifetime data. The Annals of Statistics 2006; 34(1):290Ű325, the treatment effect can be modeled as a flexible function of the biomarker. In this paper, we propose a bootstrap test method for survival outcome data based on the LPLE, for assessing whether the treatment effect is a constant among all patients or varies as a function of the biomarker. The test method is called local partial-likelihood bootstrap (LPLB) and is developed by bootstrapping the martingale residuals. The test statistic measures the amount of change in treatment effects across the entire range of the biomarker and is derived based on asymptotic theories for martingales. The LPLB method is nonparametric and is shown in simulations and data analysis examples to be flexible enough to identify treatment effects in a biomarker-defined subset and more powerful to detect treatment-biomarker interaction of complex forms than the Cox regression model with a simple interaction. We use data from a breast cancer and a prostate cancer clinical trial to illustrate the proposed LPLB test.

Keywords: bootstrap; clinical trials; nonparametric estimation; survival analysis; treatment-covariate interaction.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers*
  • Breast Neoplasms / drug therapy
  • Female
  • Humans
  • Likelihood Functions*
  • Male
  • Precision Medicine* / statistics & numerical data
  • Prostatic Neoplasms / drug therapy
  • Survival Analysis
  • Treatment Outcome

Substances

  • Biomarkers